Bal Pharma Q2 Results: Consolidated Net Profit Surges 99.8% YoY
Bal Pharma Ltd · Outcome · 11 Nov 2026, 11:46 pm
Bal Pharma Q2 Results: Consolidated Net Profit Surges 99.8% YoY Bal Pharma reported a 21.5% YoY rise in consolidated revenue from operations to ₹8,994.69 lakhs for the quarter ended 30th Sep'26, up from ₹7,402.49 lakhs in Q2 of the prior year. Consolidated net profit surged 99.8% YoY to ₹143.31 lakhs compared to ₹71.73 lakhs, with basic EPS improving to ₹0.89 from ₹0.45. Additionally, the company confirmed zero deviation in the utilization of ₹210.00 lakhs raised via preferential warrant allotments earmarked for its Greenfield API manufacturing facility in Yadgiri, Karnataka.
Original exchange filing (PDF)
More announcements from Bal Pharma Ltd
- In Continuation of outcome of Board meeting dated 11th November 2026, published unaudited financial result for the 02nd quarter and half year ended 30th September 2026. Copy of the newspaper .... · 12 Nov 2026
- Bal Pharma Limited has informed the Exchange regarding Outcome of Board Meeting held on November 11, 2026.As intimated vide our letter dated November 03, 2026, Board of directors of the Company met on Wednesday, November 11, 2026 inter alia transacted the following business.1. Considered and approved the unaudited Financial Results (Standalone and Consolidated) of the Company for Second quarter and Half year ended on 30th September, 2026. copy of the approved financial results together with the · 12 Nov 2026
- Enclosed Statement of Utilization of issue proceeds raised through preferencial issue of warrants. Confirming that No Deviation or Variation in issue proceed for which fund has raised. · 11 Nov 2026
- Enclosed unaudited standalone and consolidated Financial Result of Second quarter 30th September 2026 along with Limited Review Report · 11 Nov 2026
- To consider and approve the financial results for the period ended September 30, 2026 and other business matters · 11 Nov 2026
- BAL PHARMA LIMITED has informed the Exchange about Board Meeting to be held on 11-Nov-2026 to consider and approve the Quarterly Unaudited Financial results of the Company for the period ended September 2026 and Other business. · 11 Nov 2026
- Bal Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 11/11/2026 ,inter alia, to consider and approve unaudited (Standalone and Consolidated) .... · 11 Nov 2026
- Dividend payment Update - Intimation regarding disbursement of final dividend for the Fy 2025-26 and withholding of dividend in respect of shareholders with incomplete KYC / bank account details · 13 Oct 2026
